Exempting Small Biotech Firms from Medicare Drug Price Negotiation Program.
This bill creates a new exception to the Medicare drug price negotiation program, starting in 2029. It protects drugs made by small biotechnology companies that heavily invest in research and development (R&D). The goal is to ensure these smaller firms can continue innovating without immediate price controls, potentially leading to new treatments.
Key points
Small biotech companies that invest significantly in R&D are exempt from mandatory Medicare drug price negotiations.
The required R&D investment percentage varies based on how many drugs the company currently sells (30% to 70% of net revenue).
If a small company is acquired by a larger manufacturer that does not meet the R&D criteria, the drug loses its price negotiation exemption.
Status:
Expired
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens
(explained here).
Start recording it now.